ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
RemeGen Announced Highly Encouraging Data from the Phase II Clinical Trial Evaluating Disitamab Vedotin plus Immunotherapy as Perioperative Regimen for Bladder Cancer
February 15, 2025At 2025 ASCO GU, Prof. Xinan Sheng disclosed phase II trial data of DV + Toripalimab for HER2 - expressing MIBC, showing high pCR and manageable safety. -
Results Unveiled for the Phase III Study of Disitamab Vedotin in Treating HER2-Positive Advanced Breast Cancer with Liver Metastasis
December 13, 2024Results Unveiled for the Phase III Study of Disitamab Vedotin in Treating HER2-Positive Advanced Breast Cancer with Liver Metastasis -
Seagen and RemeGen enter up to $2.6bn deal for cancer drug
August 11, 2021Seagen and a Chinese company, RemeGen, have signed an exclusive global licencing agreement to develop and market a new HER2-targeted antibody-drug conjugate (ADC), disitamab vedotin.
Pharma Sources Insight January 2025
